Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2006

View Archived Issues

Lipid Sciences files IDE for Plasma Delipidation System-2

Private placement funds to support phase II Reolysin development

Zydus Cadila files IND for antiinflammatory compound ZYI-1

Samaritan initiates new phase IIb for SP-01A in HIV

Positive results from synDNA hepatitis B study

InSite Vision completes debt refinancing to support AzaSite development and filing

Recordati signs agreement with Osmotica for modified-release lercanidipine

sNDA submission for Seroquel in bipolar depression

Cerus files IND for phase I study of CRS-100

New designer antibacterial agents from Rib-X Pharmaceuticals

MBX-037 demonstrates antibacterial potential of DNA polymerase IIIC inhibitors

New agents with activity against HIV reported in patent literature

New agents and strategies for respiratory disorders

Cervical cancer vaccine induces greater response in younger women

Inhaled aztreonam reduces P. aeruginosa in cystic fibrosis patients

NDA submission for telbivudine in chronic hepatitis B

U.S. launch for Increlex

Symadex studied in metastatic breast cancer

KRX-0401 studied in new phase II trial for multiple myeloma

Selective targeting of the immunoproteasome for hematologic malignancies

Nonapprovable letter for Cesamet labeling changes

AZD-2479 for dyslipidemia begins phase I study

Studies reveal antibiotic activity of CSA-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...